AI app aims to cut heart attack deaths by getting Clot-Busting drugs to patients faster

NCT ID NCT07160491

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether an artificial intelligence (AI) mobile app can help doctors give clot-busting medicine earlier to people having a severe heart attack (STEMI) when a hospital procedure isn't possible within 2 hours. About 3,356 participants will be randomly assigned to get either standard care or care guided by the app. The goal is to see if the app reduces deaths, strokes, and other major heart problems over one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

tenecteplase (clot-busting drug) and an AI-assisted mobile app to guide treatment

What this could lead to

If successful, this could provide a reliable way to deliver faster, life-saving heart attack treatment in remote areas or when hospital procedures are delayed.

What could go wrong

This is a large trial, but the AI app is new and unproven. The benefit depends on how well it works in real-world settings, and there are always risks with clot-busting drugs, like bleeding.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STEMI - ST ELEVATION MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myocardial infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • No. 83, Wenhua Road, Shenhe District, Shenyang City

    RECRUITING

    Shenyang, Liaoning, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••